MorphoSys, Pfizer Ink Technology Alliance

MorphoSys AG has signed a non-exclusive license and technology transfer agreement between its subsidiary, Sloning BioTechnology GmbH and Pfizer, for the installation, training and use of Sloning’s Slonomics technology platform for fabrication of diverse gene and protein libraries at Pfizer’s subsidiary Rinat Neuroscience Corp. The MorphoSys subsidiary will receive an upfront payment and is eligible to receive annual license fees for use of the Slonomics technology platform. Financial details were not disclosed.

“This significant alliance around the Slonomics technology, only weeks after we closed the acquisition of Sloning, clearly illustrates the potential value of the platform,” said Dr. Simon Moroney, chief executive officer of MorphoSys AG. “This alliance with Pfizer creates immediate value for our shareholders and is just the beginning of what we expect to be a considerable return-on- investment from the combined technology platforms of MorphoSys and Sloning in the years ahead.”

“Rinat started using Sloning’s services in 2009, and we were impressed by the diversity and quality of the libraries delivered,” said Jaume Pons, Ph.D., chief scientific officer at Pfizer’s Rinat subsidiary. “We therefore decided to use this innovative technology platform further for our research and development activities.”